Identifying potential therapeutic targets for prostate cancer with mediating role in tumor immunity.

ABSTRACT:

Background

Prostate cancer (PCa) is a leading malignancy with a rising global incidence, posing significant challenges in treatment. The immunosuppressive tumor microenvironment (TME) in castration-resistant prostate cancer (CRPC) is a major barrier to effective immunotherapy. Identifying therapeutic targets that modulate the immune response within TME is crucial for advancing PCa treatment.

Materials and methods

In this study, we employed Mendelian randomization (MR) to investigate the causal relationships between gene expression of blood proteins and PCa risk. We utilized cis-eQTL data from the eQTLGen Consortium and immune cell phenotype data from the NHGRI-EBI GWAS Catalog. Our analysis included primary and secondary cohorts, totaling over 800,000 individuals. Colocaliza

SUBMITTER: Wu Z 

PROVIDER: S-EPMC12433928 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature